GSK enters agreement to acquire IDRx for $1.15 Billion to strengthen cancer portfolio
UK pharmaceutical giant GSK has confirmed that it has signed an agreement to acquire the privately-held biotechnology company IDRx.
UK pharmaceutical giant GSK has confirmed that it has signed an agreement to acquire the privately-held biotechnology company IDRx.
